obeticholic acid

Obeticholic Acid (6-ECDCA, INT-747) is a high-affinity, semisynthetic, bile acid-derived FXR agonist with an EC50 of 99 nM and is able to upregulate IκB-α, KLF-2, and KLF-4 expression. Obeticholic Acid (6-ECDCA, INT-747) also shows potential for treating hepatic steatosis, inflammation, and fibrosis while increasing insulin sensitivity.

Glyco-Obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an agonist of the farnesoid X receptor (FXR).

Tauro-Obeticholic acid is an active Obeticholic acid metabolite. Obeticholic acid is an orally bioavailable agonist of farnesoid-X receptor (FXR).

Obeticholic Acid-d4 is the deuterated form of Obeticholic acid. Obeticholic acid (INT-747) acts as a potent, selective, and orally active FXR agonist, with an EC50 of 99 nM, exhibiting both anticholestatic and anti-inflammatory properties. Additionally, Obeticholic acid can induce autophagy (autophagy).

Obeticholic acid-d5 is the deuterated form of Obeticholic acid. Obeticholic acid (INT-747) acts as a potent, selective, and orally active FXR agonist with an EC50 of 99 nM, exhibiting both anticholeretic and anti-inflammatory properties. Additionally, Obeticholic acid can induce autophagy (autophagy).